Why are eligible patients not prescribed aspirin in primary care?: a qualitative study indicating measures for improvement by Short, D et al.
BioMed CentralBMC Family Practice
ssOpen AcceResearch article
Why are eligible patients not prescribed aspirin in primary care? A 
qualitative study indicating measures for improvement
Duncan Short*1, Martin Frischer1, James Bashford1 and Darren Ashcroft2
Address: 1Department of Medicines Management, University of Keele, Keele, Staffordshire, UK, ST5 5BG and 2School of Pharmacy and 
Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK, M13 9PL
Email: Duncan Short* - d.short@keele.ac.uk; Martin Frischer - m.frischer@keele.ac.uk; James Bashford - j.n.r.bashford@keele.ac.uk; 
Darren Ashcroft - darren.ashcroft@man.ac.uk
* Corresponding author    
Abstract
Background: Despite evidence-based guidelines, aspirin prescribing for the secondary prevention
of stroke is sub-optimal. Little is known about why general practitioners do not prescribe aspirin
to indicated patients. We sought to identify and describe factors that lead general practitioners
(GPs) not to prescribe aspirin to eligible stroke patients. This was the first stage of a study exploring
the need for and means of improving levels of appropriate aspirin prescribing.
Method: Qualitative interviews with 15 GPs in the West Midlands.
Results: Initially, many GPs did not regard their prescribing as difficult or sub-optimal. However
on reflection, they gave several reasons that lead to them not prescribing aspirin for eligible patients
or being uncertain. These include: difficulties in applying generic guidelines to individuals presenting
in consultations, patient resistance to taking aspirin, the prioritisation of other issues in a time
constrained consultation and problems in reviewing the medication of existing stroke patients.
Conclusion: In order to improve levels of appropriate aspirin prescribing, the nature and
presentation risk information available to GPs and patients must be improved. GPs need support
in assessing the risks and benefits of prescribing for patients with combinations of complicating risk
factors, while means of facilitating improved GP-patient dialogue are required to help address
patient uncertainty. A decision analysis based support system is one option. Decision analysis could
synthesise current evidence and identify risk data for a range of patient profiles commonly
presenting in primary care. These data could then be incorporated into a user-friendly
computerised decision support system to help facilitate improved GP-patient communication.
Measures of optimum prescribing based upon aggregated prescribing data must be interpreted with
caution. It is not possible to assess whether low levels of prescribing reflect appropriate or
inappropriate use of aspirin in specific patients where concordance between the GP and the patient
is practised.
Background
Aspirin is an internationally recognised cost-effective
treatment for patients with vascular disease [1]. Prescrib-
ing in general practice however has been consistently
reported to be sub-optimal despite evidence that the ben-
efits of therapy significantly outweigh the risks for the
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lished to assist practitioners, but many patients for whom
aspirin may be beneficial do not receive therapy [5–7].
Improving appropriate prescribing of aspirin is a health
service priority [2].
The gap between evidence and practice has increasingly
been the focus of research. Several reasons have been cited
to explain why some general practitioners do not imple-
ment evidence based guidelines. These include difficulties
in reconciling generic evidence and trial data to individual
patients, concerns that decisions may jeopardise the doc-
tor-patient relationship, poor adherence to practice proto-
cols and the absence of computerised systems [8–11].
It is not known whether these reasons cited for other ther-
apeutic areas can explain the decision not to prescribe
aspirin in eligible patients. The first stage of a process to
improve the implementation of the evidence is therefore
to identify the reasons for behaviour and the factors likely
to influence any change [12].
This paper reports a qualitative study of GPs to explore
why there continues to be a gap between prescribing goals
and prescribing practice among patients eligible for aspi-
rin. We focussed upon the secondary prevention of stroke
where aspirin is first line therapy yet estimations of use are
as low as 39% [3]. A previous quantitative study con-
cluded that there is "stated unwillingness to advise aspirin
prophylaxis by some general practitioners, even when it is
clearly indicated" [4]. The objectives of this study were to
enhance understanding of aspirin prescribing in the sec-
ondary prevention of stroke by exploring difficulties GPs
have in deciding whether or not to prescribe for eligible
patients and the reasons that they give for not prescribing.
Method
After approval from the local research ethics committee,
fifteen GPs from nine practices in the West Midlands
region agreed to take part in the study. The practices were
part of a research network established by the Department
of Medicines Management, Keele University and varied in
size, type of location and catchment area. All forty-five
GPs from the network were invited to participate.
As this was a qualitative study, respondents do not consti-
tute a representative sample, but their accounts illustrate a
range of experiences and views on prescribing aspirin for
patients in general practice. Respondents varied in age, sex
and length of time that they had been qualified as a GP.
Table 1 shows the characteristics of the interviewees. The
sample size was sufficient to reach theoretical saturation.
All interviews lasted between 25 and 35 minutes and were
conducted by DS in GP practices. These were based upon
a topic guide developed by the authors that was informed
by a review of published studies and a pilot interview with
a GP. The schedule comprised questions exploring: initial
reactions to whether there are difficulties in prescribing
aspirin; opinions of published evidence suggesting subop-
timal prescribing; the ease of implementing national
guidelines; examples of GPs' own prescribing uncertainty
or difficulties.
All interviews were tape-recorded and transcribed verba-
tim with the consent of each participant. Transcripts were
analysed for major themes through an iterative process of
comparison and evaluation. Each were revisited and
revised as further data was gathered. DS led on analysis
and met with MF and JB regularly to discuss shared tran-
scripts. Emergent themes were examined and raised in
subsequent interviews with practitioners [13,14].
Results
The interviews identified a range of experiences and views
concerning the prescribing of aspirin for the secondary
prevention of stroke. GPs' initial reactions contrasted with
thoughts regarding prescribing once the area was explored
in more detail; in particular, in scenarios in which GPs
described experiencing difficulties or uncertainty in mak-
ing judgements and decisions.
'Aspirin – what problem?' – Initial reactions of GPs
The immediate reaction of most GPs when asked whether
aspirin prescribing presents a difficulty was that it is rela-
tively straightforward. Practitioners expressed great confi-
dence in their own decision making, seemed very clear
about contraindications for prescribing and said it was a
straightforward recommendation for most patients.
"I can't understand why GPs aren't using it by the bucket-
ful." GP08
"...for the vast majority, it's quite an easy decision. You do
it if there are no obvious contraindications." GP13
All of the GPs were nevertheless acutely aware of the evi-
dence highlighting suboptimal prescribing. Many
acknowledged that some patients do not receive aspirin
who would benefit from therapy, but opinions about such
prescribing varied. Some showed some empathy with the
difficulties experienced by GPs, while others were less
understanding.
"Some clinicians feel that they understand the issues but
it is fairly obvious that there is a significant body that
don't." GP01Page 2 of 7
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reading of the recommendations is that they are quite
straightforward." GP02
As each interview progressed, however, prescribing deci-
sions were revealed to be much more complicated than
they may have appeared on the surface. Exploration of dif-
ficult situations highlighted that decision-making was less
clear than initially suggested and that the issue had at
times presented difficulties for all practitioners. Prescrib-
ing uncertainty and reasons for indicated patients not
being prescribed aspirin were detailed.
Difficulties in prescribing aspirin
Difficulties with aspirin prescribing could be broadly cat-
egorised into three areas: Those arising from (a) clinical
uncertainty (b) patient resistance (c) other
considerations.
(a) Clinical uncertainty
All of the practitioners said that decision making regard-
ing aspirin was not as straightforward as guidelines may
imply. Many stated that there were numerous occasions
when they found it difficult to apply generic guidelines to
individual patients.
" [Aspirin guidelines] tend to be fairly simple and linear.
But the kind of situations we are in are messy and unpre-
dictable and complicated...it's difficult to work out what
you should do." GP14
"... for the individual, a guideline cannot indicate what is
right .... they are just not specific." GP05
Several factors inhibiting the application of guidelines
were frequently cited:
(i) Complexity of individual cases
Certain patient characteristics introduced an element of
uncertainty about recommending aspirin because of how
this affected the balance of risks and benefits for that indi-
vidual. For example:
– Patients with a history of GI disease, such as dyspepsia
or ulcers.
"What do you do with people who have previous GI
bleeds? ... Those are big decisions that put you off. ...I
would need a lot of confidence to say that that was still the
right decision." GP03
– The 'very elderly'.
"... because of their risk of GI disease" GP04
– Patients taking non-steroidal anti-inflammatory drugs.
"Certainly patients on anti-inflammatories it is a difficult
decision. ...You have some feel for what sort of effect [on
the risk of a bleed] an anti-inflammatory will have but you
can't quantify it." GP04
(ii) Incomplete patient information
Another area that presented difficulty for GPs was where
there was uncertainty concerning the information that
they had available to make their decision. This may be
because of incomplete patient records or if a patient's
recall of prior events conflicts with their notes.
"...they say they have vomited blood in the past and you
are not quite sure – it is not documented elsewhere. Some-
times looking for corroboration in the records is difficult."
GP14
(iii) Aetiology of the initial stroke
A further difficulty described by GPs was when the aetiol-
ogy of the initial stroke is unknown. Aspirin should not be
prescribed to patients whose first stroke is haemorrhagic
and ideally GPs would have this information from a com-
puterised tomography (CT) scan. However, many patients
may not undergo such a procedure.
Table 1: Characteristics of GPs interviewed
Total number interviewed n = 15
Gender
Male n = 13
Female n = 2
Age (years) Mean 45 Range 34–59
GP Principals n = 15
Number of years practising Mean = 16; range 6–34
Number of partners in their practice Mean = 4 Range 1–8
Number recording consultation notes on their computer n = 15Page 3 of 7
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and we are not referring them...they are not going to get a
scan." GP14
This uncertainty about the nature of the stroke is problem-
atic and several said that it increased their anxiety about
recommending aspirin. Several said that in such circum-
stances, based upon probability, they assumed the first
event was ischaemic rather than haemorrhagic.
"...what I do in practice is assume that it is a non-haemor-
rhagic stroke and prescribe but I'm very uneasy about
that." GP02
"Obviously in the ideal world you scan them all and you
get the answer, but that just isn't feasible. As I understand
it, statistically only 15% of strokes are haemorrhagic so
the chances are it isn't that." GP15
One GP described a case where they had considered but
not prescribed aspirin:
"... in the back of my mind is the balance between haem-
orrhagic strokes and thrombotic strokes. ... I can well
remember the day when I had a [stroke] patient and said
'really you ought to be on aspirin', and the guy said 'I'm
going to go away and think about it.' He was in his forties,
and he walked out of the door of the surgery and fifteen
minutes later he collapsed with a haemorrhagic stroke
and survived. I remember thinking if I had stuck that guy
on aspirin he would be dead. And that lurks in the back of
my mind... You know that you are going to make some
patients more likely to have haemorrhagic events". GP13
This practitioner said that the incident had a powerful
influence on their future decision making concerning
aspirin.
(b) Prescribing difficulties arising from patients' reluctance to take 
aspirin
Patients' reluctance to taking aspirin was also identified as
a key factor contributing to the non-prescribing of aspirin
to indicated patients. In such cases, practitioners said that
if they felt aspirin would be beneficial to the patient then
they would usually try and encourage them to take this
but that some still chose not to take it.
Reluctant patients described by GPs tended to fall into
one of three categories:
(i) Patients haunted by the "ghosts of doctors past"
Some patients were said to be determined to adhere to a
previous clinician's instruction 'never' to take aspirin
again, regardless of their current GP's advice.
"A lot of patients are stuck in the frame that 'my doctor 20
years ago said I should never take aspirin'. And if you've
been in with a GI bleed and your consultant said never
take aspirin, then that becomes a very ingrained message
... people often do not recognise that information changes
with time, and that messages from somebody who saved
their life 20 years ago may not be right now." GP03.
(ii) Patients with knowledge of bad experiences with aspirin
Further patient resistance can be attributed to negative
experiences associated with aspirin for themselves, family
or friends.
"If you are a patient and you have vomited blood it's a
pretty scary experience and most of them wouldn't want
to go through it again" GP03
"I have one old lady who won't take it because one of her
relatives committed suicide with aspirin. There is no way
you can make her take aspirin ... nothing will change
that." GP12
(iii) Patients beliefs
Some patients were said to have beliefs about aspirin that
the GPs viewed as irrational. Practitioners said that it was
very difficult to reassure these individuals regarding aspi-
rin and overcome this mindset.
"...some people who have asthma are reluctant to take
anything 'aspiriny'.... whether they have got an allergy or
not." GP10
Overall, communicating the benefits and risks of the deci-
sion to patients was an issue for many GPs. They reported
cases where they felt the benefits of aspirin significantly
outweighed the risks, but patients were reluctant to take
the drug and they did not feel that they could sufficiently
reassure them of their recommendation.
(c) Other considerations contributing to non-prescribing for eligible 
patients
Several other difficulties for GPs were identified by inter-
viewees that may contribute to indicated patients not
receiving prophylactic aspirin:
(i) GPs' perceptions of the benefits of aspirin
Uncertainty among some GPs regarding the evidence for
aspirin was perceived as a barrier to optimum prescribing:
" People have taken a long time to be able to work out
what the evidence really is." GP14
"I think we underestimate the benefits of something that
seems so simple. It's just aspirin. It's not expensive, it's not
new, it's not anything else. It's just aspirin. ... you'rePage 4 of 7
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looking at lipids and then suddenly think 'ooh aspirin'
...we maybe underestimate its importance." GP03
(ii) Problems in reviewing aspirin use among existing stroke patients
GPs described problems in reviewing the medication of
long-standing patients. For example, patients may not be
seen in routine consultations and therefore reviews may
not be carried out.
"We have a burden of people who have already had
strokes, that we are not necessarily revisiting ... we may
not see them from one month to another and we therefore
don't review the decision as to whether they are on aspirin
or not." GP03
"The foremost problem is that the doctor and the patient
don't meet for whatever reason." GP13
Furthermore, even if patients do present in primary care,
they may still not be identified as potentially in need of
aspirin.
"I think far more of a problem with prescribing is not
thinking about it in the first place or not having a set sys-
tem in place where the system tags up 'why is this patient
not on aspirin?"' GP12
Variations in the computerisation of practices was one
explanation suggested for problems in identifying
patients for review.
"...if you can produce a report showing that only 10% are
on aspirin then straight away it stirs you into action, but if
you can't do that, ...you are not going to do anything.."
GP07
(iii) Practical difficulties
Many GPs described the nature of a time-constrained con-
sultation as not conducive to optimum prescribing. For
example, for new stroke patients the GP may have higher
priority issues than prophylaxis to address such as mobil-
ity and wider stroke management issues.
"The priorities on discharge may be ... 'are they mobile?',
'are they continent?', 'are they in a second floor flat?' and
all those sorts of issues probably come to the fore, not 'are
they taking aspirin?"' GP03
A further practical difficulty described was that the consul-
tation agenda may be dictated by the patient's immediate
practical needs.
"... sometimes for elderly people presenting after a stroke,
... future prevention, may not be their priority... you only
have 10 minutes for your patient ... and they might be
much more worried about a handrail to get up and down
the stairs." GP14
"The patient may come and present an agenda around ...
arthritis, depression, whatever, and so within a consulta-
tion we may have other things going on other than some-
thing that is effectively preventative medicine. And you
have to concentrate upon the patient's agenda." GP13
Given the time pressures of primary care consultations,
such issues can lead to aspirin not being considered.
(iv) The benefits of prophylaxis for very ill patients
GPs also reported uncertainty about the benefits aspirin
prophylaxis when considering the decision for patients
with extremely poor health and poor prognosis. In some
cases GPs said that they feel that patients may experience
longer life if they took aspirin, but that this may not be in
the patient's interests because of their very limited quality
of life.
"you may feel that the sort of benefits they are likely to get
are not that great because the quality of their life is pretty
dismal." GP10
(v) Fear of being challenged by stroke patients
A lesser theme was that some GPs expressed anxiety about
patients' reactions to starting them on aspirin for the first
time, if their initial stroke was a long time ago. The poten-
tial for patients to challenge the GP because of their time
without therapy was an issue.
"It is easy to fall through the net. Several times I have done
it myself ... I mean a chap came in, ... said 'why haven't I
had aspirin before?' ... I had seen him so many times I just
hadn't got round to doing it. ... he should have been on
it." GP12
Discussion
Following the publication of the National Service Frame-
work (NSF) for Coronary Heart Disease in 2000 it is a pri-
ority to improve levels of appropriate aspirin prescribing.
This study has provided fresh insight into the difficulties
facing general practitioners. A range of reasons why prac-
titioners may not prescribe aspirin to eligible patients
have been identified, which include reservations resulting
from clinical uncertainty, patients' reluctance to taking
aspirin, perceived benefits of treatment, and issues relat-
ing to pragmatism. In practice, these issues have impor-
tant implications if prescribing targets are used to monitor
the quality of care provided to patients.
One major theme to emerge was the difficulties that prac-
titioners have in applying general guidelinePage 5 of 7
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a personal set of histories and risks. Welton and col-
leagues showed quantitatively that many GPs responded
to complex cases by not prescribing and our study has
provided qualitative detail to reinforce this belief [4].
Every practitioner described patients with whom they had
struggled to apply the guideline as other factors had com-
plicated their judgement and led them to question
whether the benefits outweigh the risks. Simple reinforce-
ment of existing guidelines cannot resolve this uncer-
tainty. There is a need to develop more detailed guidance
closer to individual patients' characteristics or target addi-
tional education based upon real life cases to clarify risks
and benefits for prescribers faced with patients of particu-
lar risk profiles. Decision analytical modelling is one
potential means of addressing this. Decision analysis is a
means of synthesising current evidence and models could
be pre-calculated for a number of patient profiles com-
monly presenting in primary care. The results could then
be incorporated into a support system for GPs to access in
a consultation.
Patient reluctance to take aspirin was also reported to be
an important barrier to prescribing. Even when GPs are
confident of the benefits of aspirin, patients may still
decide that they would prefer not to receive therapy. Such
patient reservations have been identified in other disease
contexts [15,16]. Many general practitioners who were
interviewed often felt unable to adequately communicate
the reason for their recommendation to patients who
expressed concerns. Current guidance gives insufficient
weight to the patient's perspective of risks and improved
means of facilitating improved GP-patient dialogue
around aspirin therapy is required. Decision support sys-
tems have been shown to increase patients' knowledge
and agreement between patients' values and decisions,
and is one potential solution [17].
It is however important to recognise that a concordant
consultation about aspirin may result in an informed
patient declining therapy and that this is acceptable [18].
In striving to meet the needs of the NSF, GPs may inappro-
priately feel that they have failed if the patient does not
accept treatment. If we accept that informed patients can
choose not to receive therapy, then care is required when
using aggregated aspirin prescribing data as a measure of
optimum prescribing. In the absence of individual details,
it is not possible to be sure whether low levels of prescrib-
ing reflect appropriate or inappropriate use of aspirin in
specific patients. Individual circumstances for each deci-
sion and patient choice are key determinants of whether
or not patients receive treatment and in a healthcare sys-
tem that encourages concordance between the GP and the
patient, such a measure may be an unreliable indicator of
prescribing quality. If the new GP contract is implemented
there may be the facility to record in prescribing data the
patients who make informed decisions not to accept a
medical recommendation. Current aggregated data how-
ever must nevertheless be interpreted with caution.
Conclusion
In order to improve the appropriate prescribing of aspirin
for eligible patients, further research should examine both
GPs' and patients' information needs. A failure to ade-
quately support practitioners' decision-making or ensure
that this can be effectively communicated will inevitably
lead to uncertainty and misunderstandings about the risks
and benefits of treatment for individual patients. Support
systems underpinned by evidence-based decision analyti-
cal models of patient profiles are one potential means of
assisting many practitioners in their decision making.
Furthermore, measures of suboptimal prescribing based
upon aggregate prescribing data should be interpreted
with caution in the absence of more detailed assessment
of issues concerning the individual patient.
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